ArticleThe Eurasian journal of medicine2026
Dose or Timing? The Role of Prophylaxis in Preventing Joint Bleeds in Hemophilia: A Cross-Generational Comparative Analysis.
Article in The Eurasian journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to assess intergenerational differences in joint health and functional independence among adults with hemophilia and to examine the relationship between prophylaxis timing, dose intensity, and treatment adherence and long-term joint outcomes.
methodsA retrospective study was conducted including 91 adult patients with hemophilia A or B. Participants were classified into generational cohorts within different treatment eras. Joint health and functional status were assessed using the Hemophilia Joint Health Score (HJHS) and the Functional Independence Score in Hemophilia (FISH). Statistical analyses included correlation analyses, subgroup comparisons, and general linear models; subgroup analyses were considered exploratory.
resultsThe median age was 38 years, and prophylaxis was initiated at a median age of 27 years. Patients had a mean annual bleeding rate of 11.1, with a median of 2 joints affected per year, most commonly the ankles, knees, and elbows. The median prophylaxis dose was 20.8 IU/kg, and bleeding episodes significantly decreased in patients requiring dose escalation (P = .007). Higher joint scores were associated with poorer functional outcomes and a greater number of bleeding joints. Joint health and functional outcomes differed significantly across generations (P < .001), with worse outcomes in older cohorts. Follow-up showed no significant improvement over 1 year, although baseline and follow-up joint scores were strongly correlated (P < .001).
conclusionIn adults with hemophilia, delayed prophylaxis initiation was associated with poorer joint and functional outcomes. The observed intergenerational differences likely reflect historical variations in access to prophylaxis and treatment practices. Although individualized dose escalation improved bleeding control, established joint damage showed limited short-term reversibility. Cite this article as: Demirci Z, Soyer N, Keklik Karadağ F, Arslan A, Saydam G, Şahin F. Dose or timing? The role of prophylaxis in preventing joint bleeds in hemophilia: a cross-generational comparative analysis. Eurasian J Med. 2026, 58(4), 1208, doi: 10.5152/eurasianjmed.2026.251208.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.